Search

Voacamine

Voacamine is an alkaloid isolated from the bark of the _Pescheria fuchsiae folia_ tree. It is an antimalarial drug approved for use in several African countries. … Voacamine is also under investigation for use in modulating multidrug-resistance in tumor cells.

Oveporexton

[L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … Oveporexton is an orally administered orexin receptor 2 (OX2R) agonist used to treat narcolepsy type 1 (NT1).

Rose bengal I-131

Enzalutamide

[L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007.

Daclizumab

in de novo allogeneic renal transplantation and used concomitantly with an immunosuppressive regimen like cyclosporine and corticosteroids in patients who are not hight immunized, for commercial reasons … Despite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and

Depreotide

Depreotide is an ingredient in the EMA-withdrawn product NeoSpect.

Hesperidin

Hesperidin is a flavan-on glycoside found in citrus fruits.

Droloxifene

Its higher affinity to the estrogen receptor, higher anti-estrogenic to estrogenic ratio, more effective inhibition of cell growth and division in estrogen receptor-positive cell lines, and lower toxicity … It may have a particular role in situations in which rapid pharmacokinetics, or an increased antiestrogenic to estrogenic ratio, are required.

Rapacuronium

Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm.

Cod liver oil

It is used as an adjunct treatment and preventative therapy of rickets, osteomalacia and osteoporosis while meeting the consumption criteria.